A Randomized, Open-Label, 2 x 2 Crossover Phase 1 Study to Evaluate the Food Effect on the Pharmacokinetics (PK) and safety of Single Oral Dose of Azilsartan (TAK-536) Pediatric Formulation (10 mg) in Healthy Adult Male Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Azilsartan (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Takeda Pharma
- 26 Mar 2018 Status changed from recruiting to completed.
- 16 Feb 2018 Status changed from not yet recruiting to recruiting.
- 09 Feb 2018 New trial record